UA104875C2 - Препарат на основі синтетичних міметиків та спосіб одержання синтетичних міметиків (варіанти) - Google Patents

Препарат на основі синтетичних міметиків та спосіб одержання синтетичних міметиків (варіанти)

Info

Publication number
UA104875C2
UA104875C2 UAA201106679A UAA201106679A UA104875C2 UA 104875 C2 UA104875 C2 UA 104875C2 UA A201106679 A UAA201106679 A UA A201106679A UA A201106679 A UAA201106679 A UA A201106679A UA 104875 C2 UA104875 C2 UA 104875C2
Authority
UA
Ukraine
Prior art keywords
synthetic mimetics
epreparation
preparation based
mimetics
synthetic
Prior art date
Application number
UAA201106679A
Other languages
English (en)
Russian (ru)
Inventor
Уілльям Ф. Деградо
Дахой ЛЮ
Річард У. Скотт
Юнцзян СЮЙ
Хайчжун ТАН
Божена КОРЧАК
Original Assignee
Селлсьютікс Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селлсьютікс Корпорейшн filed Critical Селлсьютікс Корпорейшн
Publication of UA104875C2 publication Critical patent/UA104875C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Даний винахід стосується препарату на основі ариламідних сполук загальної формули І й способів їх одержання. EMBED MDLDrawOLE.MDLDrawObject.1 (І)
UAA201106679A 2008-10-27 2009-10-27 Препарат на основі синтетичних міметиків та спосіб одержання синтетичних міметиків (варіанти) UA104875C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10859508P 2008-10-27 2008-10-27
US12/605,584 US8278309B2 (en) 2008-10-27 2009-10-26 Synthetic mimetics of host defense and uses thereof
PCT/US2009/062147 WO2010062573A1 (en) 2008-10-27 2009-10-27 Synthetic mimetics of host defense and uses thereof

Publications (1)

Publication Number Publication Date
UA104875C2 true UA104875C2 (uk) 2014-03-25

Family

ID=42118100

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201106679A UA104875C2 (uk) 2008-10-27 2009-10-27 Препарат на основі синтетичних міметиків та спосіб одержання синтетичних міметиків (варіанти)

Country Status (14)

Country Link
US (2) US8278309B2 (uk)
EP (1) EP2358380A4 (uk)
JP (1) JP2012506908A (uk)
KR (1) KR20110074995A (uk)
CN (1) CN102256614B (uk)
AU (1) AU2009320139B2 (uk)
BR (1) BRPI0920251A2 (uk)
CA (1) CA2741764A1 (uk)
IL (1) IL212275A0 (uk)
MX (1) MX2011004360A (uk)
RU (1) RU2540077C2 (uk)
TW (1) TWI478915B (uk)
UA (1) UA104875C2 (uk)
WO (1) WO2010062573A1 (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
US8278309B2 (en) * 2008-10-27 2012-10-02 Polymedix, Inc. Synthetic mimetics of host defense and uses thereof
TWI520951B (zh) * 2011-05-16 2016-02-11 塞爾西優蒂克斯公司 用於治療粘膜炎的化合物
US9758607B2 (en) 2013-10-10 2017-09-12 Research Foundation Of The City University Of New York Polymer with antibacterial activity
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬
CN107574581B (zh) * 2017-08-03 2019-09-10 天津大学 一种抗菌性聚(ε-己内酯)/模拟抗菌肽电纺纤维膜及其制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) * 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
EP0629347B1 (en) * 1992-01-23 1997-07-02 Morinaga Milk Industry Co., Ltd. Antibacterial agent and treatment of article therewith
CA2340912C (en) * 1998-08-20 2008-11-18 University Of North Carolina At Chapel Hill Dicationic dibenzofuran and dibenzothiophene compounds and methods of use thereof
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP2001261674A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
FR2813080B1 (fr) * 2000-08-17 2002-11-29 Stago Diagnostica Peptides anti-heparine
CA2434961C (en) * 2000-11-08 2010-05-25 Bio-Concept Laboratories L-histidine in ophthalmic solutions
DK1372674T3 (da) 2001-03-08 2011-09-12 Univ Pennsylvania Facialt amphiphile polymerer som anti-infektive midler
CA2466807A1 (en) 2001-11-21 2003-06-05 Sugen, Inc. Pharmaceutical formulations comprising indolinone derivatives
WO2003100701A1 (en) * 2002-05-28 2003-12-04 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
JP2005529604A (ja) * 2002-06-13 2005-10-06 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 粗粒度モデルを用いる生体膜をシミュレートするための方法、システム、およびコンピュータプログラム製品
JP2006521355A (ja) * 2003-03-17 2006-09-21 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア・センター・フオー・テクノロジー・トランスフアー 表面的に両親媒性のポリマー及びオリゴマーならびにそれらの使用
WO2004082643A2 (fr) 2003-03-20 2004-09-30 Shiseido International France Composition cosmetique
US20050065091A1 (en) * 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
AU2005208771B2 (en) 2004-01-23 2011-11-24 The Trustees Of The University Of Pennsylvania Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
HUE058227T2 (hu) 2004-04-23 2022-07-28 Cydex Pharmaceuticals Inc DPI készítmény, amely szulfoalkil-éter-ciklodextrint tartalmaz
CN102653515A (zh) 2004-06-15 2012-09-05 宝利麦迪克斯股份有限公司 聚阳离子化合物及其用途
AU2005332637B2 (en) * 2004-07-23 2011-04-07 The Trustees Of The University Of Pennsylvania Antimicrobial copolymers and uses thereof
EP2522365B1 (en) 2004-11-24 2016-10-26 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
CA2591744A1 (en) 2004-12-21 2006-06-29 Pfizer Products Inc. Stable non-dihydrate azithromycin oral suspensions
JP2008531585A (ja) 2005-02-25 2008-08-14 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 表面が両親媒性のポリマーおよびオリゴマー、それらの組成物そして癌治療方法におけるそれらの使用
RU2325151C2 (ru) * 2006-06-29 2008-05-27 ООО "Научно-производственный центр "Амфион" Способ получения системы доставки водонерастворимых и плохорастворимых биологически активных веществ и лекарственная форма на ее основе
JP2008137978A (ja) * 2006-12-05 2008-06-19 Canon Inc カルバゾール誘導体及びこれを用いた有機発光素子
US20090092574A1 (en) * 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
MX2011000971A (es) * 2008-07-28 2011-06-24 Polymedix Inc Compuestos antipaludicos.
US8278309B2 (en) * 2008-10-27 2012-10-02 Polymedix, Inc. Synthetic mimetics of host defense and uses thereof

Also Published As

Publication number Publication date
EP2358380A1 (en) 2011-08-24
EP2358380A4 (en) 2012-05-02
JP2012506908A (ja) 2012-03-22
US8975262B2 (en) 2015-03-10
CN102256614A (zh) 2011-11-23
US8278309B2 (en) 2012-10-02
CN102256614B (zh) 2014-01-08
RU2540077C2 (ru) 2015-01-27
IL212275A0 (en) 2011-06-30
RU2011121354A (ru) 2012-12-10
AU2009320139A1 (en) 2010-06-03
TW201020249A (en) 2010-06-01
AU2009320139B2 (en) 2013-07-25
BRPI0920251A2 (pt) 2016-01-05
WO2010062573A1 (en) 2010-06-03
KR20110074995A (ko) 2011-07-05
TWI478915B (zh) 2015-04-01
MX2011004360A (es) 2011-08-12
US20100105703A1 (en) 2010-04-29
US20130090345A1 (en) 2013-04-11
CA2741764A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
PH12017502300A1 (en) Pesticidal compositions and processes related thereto
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
PH12017501298A1 (en) Pesticidal compositions and processes related thereto
PH12013502230A1 (en) Multispecific antibodies
IL211541A0 (en) Co-crystal compositions, methods of producing the same and uses thereof
TW201713640A (en) Bruton's tyrosine kinase inhibitors
AU2016204248A1 (en) Boron-Containing Molecules
MY150542A (en) Cmet inhibitors
UA104875C2 (uk) Препарат на основі синтетичних міметиків та спосіб одержання синтетичних міметиків (варіанти)
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
WO2014011906A3 (en) Irak inhibitors and uses thereof
WO2014011911A3 (en) Irak inhibitors and uses thereof
GEP20156230B (en) Forms of rifaximin and usage thereof
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
MX2012008141A (es) Compuestos y metodos.
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
PH12012501548A1 (en) Compositions comprising sugar-cysteine products
WO2011014288A3 (en) Articles having low coefficients of friction, methods of making the same, and methods of use
SI2473492T1 (sl) Postopek za pripravo(1S,4R)-2-oksa-3-azabiciklo(2.2.1)hept-5-enov
MX2010003873A (es) Aditivo para polimeros y proceso para la produccion del mismo.
WO2011031764A3 (en) Compounds and related methods of use